Feng Xie

Feng Xie

Auto-generated profile, based on publicly available information

Feng Xie

Huidu Shanghai Medical Sciences Ltd, Shanghai, P.R. China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RZRuiyun Zhang
Ruiyun Zhang
JZJingyu Zang
Jingyu Zang
DJDi Jin
Di Jin
FXFeng Xie
Feng Xie
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
HCHaige Chen
Haige Chen
Purpose: Bladder preservation is a viable option for some patients with muscle-invasive bladder cancer (MIBC), but an effective noninvasive biomarker test to accurately identify promising candidates is lacking. Here we present the clinical application of a novel tissue-agnostic, urine-based minimal residual disease (MRD) assay in the neoadjuvant setting for personalized disease surveillance and actionable target identification to facilitate bladder-sparing treatment approaches. Patients and Methods: The urinary tumor DNA (utDNA) analysis was evaluated in an investigator-initiated phase I trial RJBLC-I2N003 in which 20 patients diagnosed with resectable MIBC were treated presurgically with the PD-1 inhibitor toripalimab followed by radical cystectomy (RC). Results: We showed that neoadjuvant toripalimab therapy was feasible, safe, and induced a 40% rate (8/20) of pathologic complete response. Longitudinal utDNA profiling outperformed radiographic assessment and conventional biomarkers to predict the pathologic outcome of immune checkpoint blockade. In addition to detecting 3 exceptional responders with molecular MRD-negative status, we identified 7 other individuals characterized for utDNA response and 4 harboring FGFR3 mutants, all of whom (60%, 12/20) could have postponed or avoided RC. Conclusions: These findings demonstrate the safety and efficacy of neoadjuvant toripalimab, and suggest the immense potential of noninvasive utDNA MRD testing to guide tailored decision-making with regard to bladder preservation and change the current treatment paradigm for patients with MIBC.

15 May 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ZLZaiming Lu
Zaiming Lu
QGQiyong Guo
Qiyong Guo
ASAizhong Shi
Aizhong Shi
FXFeng Xie
Feng Xie
QLQingjie Lu
Qingjie Lu

8 August 2013 in Science China Life Sciences
Verified
Journal Article
Open access
PDF file
FXFeng Xie
Feng Xie
LLLanFang Li
LanFang Li
LCLinXi Chen
LinXi Chen

16 September 2024
Verified
Other
Open access
RZRuiyun Zhang
Ruiyun Zhang
JZJingyu Zang
Jingyu Zang
DJDi Jin
Di Jin
FXFeng Xie
Feng Xie
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
HCHaige Chen
Haige Chen
Table S1. Clinicopathological characteristics of 20 patients in our study. Table S2. Representativeness of study participants. Table S3. Adverse events associated with toripalimab. Table S4. SNVs and InDels of therapy-naïve neoplastic tissues detected by whole exome sequencing. Table S5. SNVs and InDels of basal urine samples detected by whole exome sequencing. Table S6. SNVs and InDels detected by personalized MRD panel sequencing. Table S7. SNVs and InDels detected by the fixed actionable/hotspot panel sequencing. Table S8. Mutational measurements of each urine/plasma sample in our study.

16 September 2024
Verified
Other
Open access
PDF file
RZRuiyun Zhang
Ruiyun Zhang
JZJingyu Zang
Jingyu Zang
DJDi Jin
Di Jin
FXFeng Xie
Feng Xie
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
HCHaige Chen
Haige Chen
Supplementary methods and clinical trial protocol

16 September 2024
Verified
Other
Open access
RZRuiyun Zhang
Ruiyun Zhang
JZJingyu Zang
Jingyu Zang
DJDi Jin
Di Jin
FXFeng Xie
Feng Xie
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
HCHaige Chen
Haige Chen
Purpose: Bladder preservation is a viable option for some muscle-invasive bladder cancer (MIBC) patients, but an effective noninvasive biomarker test to accurately identify promising candidates is lacking. Here we present the clinical application of a novel tissue-agnostic, urine-based minimal residual disease (MRD) assay in the neoadjuvant setting for personalized disease surveillance and actionable target identification to facilitate bladder-sparing treatment approaches. Patients and Methods: The urinary tumor DNA (utDNA) analysis was evaluated in an investigator-initiated phase I trial RJBLC-I2N003 in which 20 patients diagnosed with resectable MIBC were treated presurgically with the PD-1 inhibitor toripalimab followed by radical cystectomy (RC). Results: We showed that neoadjuvant toripalimab therapy was feasible, safe, and induced a 40% rate (8/20) of pathological complete response. Longitudinal utDNA profiling outperformed radiographic assessment and conventional biomarkers to predict the pathologic outcome of immune checkpoint blockade. In addition to detecting 3 exceptional responders with molecular MRD-negative status, we identified 7 other individuals characterized for utDNA clearance and 4 harboring FGFR3 mutants, all of whom (60%, 12/20) could have postponed or avoided RC. Conclusions: These findings demonstrate the safety and efficacy of neoadjuvant toripalimab, and suggest the immense potential of noninvasive utDNA MRD testing to guide tailored decision-making with regard to bladder preservation and change the current treatment paradigm for MIBC patients.